Authors: | Hofer, S.; Lassman, A. B. |
Article Title: | Molecular markers in gliomas: Impact for the clinician |
Abstract: | Over the last decade, understanding of glioma on a molecular level has greatly expanded. However, optimal incorporation of molecular markers into clinical care is controversial. We briefly review the potential utility of molecular stratification in refining histologic diagnosis, prognosis, and treatment decisions, focussing on 1p/19q co-deletion, MGMT promoter methylation, EGFR mutations, and IDH mutation. The most recently discovered IDH mutation is a striking example of a rapid implementation of a molecular marker for prognostication into common clinical use. © 2010 Springer-Verlag. |
Keywords: | cancer survival; protein expression; treatment outcome; unclassified drug; gene mutation; overall survival; promoter region; clinical trial; histopathology; review; erlotinib; drug dose comparison; antineoplastic agents; adjuvant therapy; cancer radiotherapy; disease free survival; temozolomide; glioma; brain neoplasms; medical decision making; epidermal growth factor receptor; neoplasm proteins; tumor markers, biological; vincristine; dna methylation; lomustine; procarbazine; molecular marker; dna; diagnostic value; glioblastoma; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; gefitinib; intermethod comparison; pharmacogenetics; methylated dna protein cysteine methyltransferase; egfr; chromosome deletion; chromosome 1p; isocitrate dehydrogenase; molecular; idh; isocitrate dehydrogenase 1; isocitrate dehydrogenase isoenzyme; 1p19q; mgmt; predictive; prognostic; chromosome 19q |
Journal Title: | Targeted Oncology |
Volume: | 5 |
Issue: | 3 |
ISSN: | 1776-2596 |
Publisher: | Springer |
Date Published: | 2010-09-01 |
Start Page: | 201 |
End Page: | 210 |
Language: | English |
DOI: | 10.1007/s11523-010-0157-2 |
PUBMED: | 20809335 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Export Date: 20 April 2011" - "Source: Scopus" |